Plasma concentrations of three methylated arginines, endogenous nitric oxide synthase inhibitors, in schizophrenic patients undergoing antipsychotic drug treatment

Nonaka-Hashida, Satoko; Sekine, Masae; Ozeki, Yuji; Fujii, Kumiko; Akiyama, Kazufumi; Saito, Kazutaka; Tsunoda, Makoto; Katane, Masumi; Saitoh, Yasuaki; Miyamoto, Tomofumi; Homma, Hiroshi

doi:10.1016/j.psychres.2016.02.029

Cited by 9 publications

(4 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, ADMA level was reduced in schizophrenic patients group that did not consume any drug during the last 5 months. This is also similar to the study of Celik et al (9,19).…”

Section: Discussionsupporting

confidence: 92%

“…In another study, short-term treatment initially creates a protection against endothelial damage which may be due to reduced agitation and activity of the autonomic nervous system, but no significant association was found between the disease severities (9). This study showed that drug consumption is a factor which increases possible risk factors in heart disease (14).…”

Section: Discussionmentioning

confidence: 66%

“…In many studies, it was found that higher levels of AD-MA is related to higher risks for acute coronary events (1,(8)(9)(10).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Comparison of serum levels of asymmetric dimethylarginine between patients who take two types of atypical anti psychotics

Safaei¹,

Manteghi²,

Shahini³

et al. 2019

Med. J. Islam. Republ. Iran

View full text Add to dashboard Cite

show abstract

“…Furthermore, ADMA level was reduced in schizophrenic patients group that did not consume any drug during the last 5 months. This is also similar to the study of Celik et al (9,19).…”

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 66%

See 1 more Smart Citation

Comparison of serum levels of asymmetric dimethylarginine between patients who take two types of atypical anti psychotics

Safaei¹,

Manteghi²,

Shahini³

et al. 2019

Med. J. Islam. Republ. Iran

View full text Add to dashboard Cite

show abstract

“…Ayrıca psikotrop kullanımı ile de NO ve L-arjinin metabolizmasında değişiklikler olabileceğine dair bulgular elde edilmiştir (MaiaDe-Oliviera ve ark. 2012, Nonaka-Hashida ve ark. 2016.…”

Section: Introductionunclassified

L-Arginine Add-On Treatment for Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study

Koçyiğit¹,

Yoca²,

Karahan³

et al. 2017

Turkish Journal of Psychiatry

View full text Add to dashboard Cite

ÖZETAmaç: Şizofrenide mevcut ilaç tedavileri kısmen etkili olduğundan güçlendirme veya kombinasyon tedavileri sık olarak uygulanmaktadır. Nitrik oksitin (NO) şizofreninin fizyopatolojisinde rol oynadığı öne sürülmektedir. L-arjinin NO öncülü olan bir esansiyel aminoasittir. Bu çalışmada şizofreni veya şizoafektif bozukluk tanısı konmuş klinik belirtileri kısmen devam eden hastaların mevcut tedavilerine eklenen L-arjinin'in, şizofreninin pozitif, negatif ve depresif belirtileri üzerindeki etkisinin incelemesi amaçlanmıştır.Yöntem: Çalışmaya 12 şizofreni veya şizoafektif bozukluk tanısı konmuş hasta dahil edilmiştir. Hastaların mevcut tedavilerine günde iki kez 3 g L-arjinin rastgele, çift kör, plasebo kontrollü ve çapraz geçişli şekilde eklenmiştir. Üç haftalık tedavi döneminin ardından 7 günlük ilaçsız dö-nem ve daha sonra ikinci 3 haftalık tedavi dönemine geçilmiştir. Current drug treatments for schizophrenia are only partially effective and combination/augmentation strategies are commonly used. Nitric Oxide (NO) may play a role in the pathophysiology of schizophrenia. L-arginine is the precursor of NO. In this study, we aimed to investigate whether L-arginine add-on to current medication might improve positive, negative, and depressive symptoms in schizophrenia/ schizoaffective disorder patients in partial remission. Method:The study was designed as a randomized, double-blind, placebo-controlled, crossover study of L-arginine 3 g b.i.d. as an add-on treatment to the patients' usual medication. Twelve patients diagnosed with schizophrenia/schizoaffective disorder were included. The duration of the treatment was 3 weeks, with a wash-out period of 7 days before alternation for the second arm. Psychopathology was assessed with the Positive and Negative Syndrome Scale (PANSS), the Calgary Depression Scale for Schizophrenia (CDSS), and the Clinical Global Impression (CGI) scales. Results: Our analyses revealed that L-arginine 6 g/day add-on to usual treatment was not superior to placebo for positive, negative, and depressive symptoms associated with schizophrenia as assessed with PANSS, CDSS and CGI scales. Conclusion:In our study, L-arginine did not seem to have an effect on schizophrenia symptoms. Studies with a larger sample size, with higher doses of L-arginine, and with a longer duration are needed for a definite conclusion.

show abstract

Circulating arginine metabolites in Alzheimer’s disease and vascular dementia: A systematic review and meta-analysis

Zinellu,

Tommasi,

Sedda

et al. 2023

Ageing Research Reviews

View full text Add to dashboard Cite

Plasma concentrations of three methylated arginines, endogenous nitric oxide synthase inhibitors, in schizophrenic patients undergoing antipsychotic drug treatment

Cited by 9 publications

References 56 publications

Comparison of serum levels of asymmetric dimethylarginine between patients who take two types of atypical anti psychotics

Comparison of serum levels of asymmetric dimethylarginine between patients who take two types of atypical anti psychotics

L-Arginine Add-On Treatment for Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study

Circulating arginine metabolites in Alzheimer’s disease and vascular dementia: A systematic review and meta-analysis

Contact Info

Product

Resources

About